RSLS Logo

ReShape Lifesciences Inc. (RSLS) 

NASDAQ
Market Cap
$2.9M
Sector
Healthcare
Industry
Medical—Devices
Rank in Sector
701 of 776
Rank in Industry
90 of 100

Largest Insider Buys in Sector

RSLS Stock Price History Chart

RSLS Stock Performance

About ReShape Lifesciences Inc.

ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the …

Insider Activity of ReShape Lifesciences Inc.

Over the last 12 months, insiders at ReShape Lifesciences Inc. have bought $0 and sold $39 worth of ReShape Lifesciences Inc. stock.

On average, over the past 5 years, insiders at ReShape Lifesciences Inc. have bought $96,625 and sold $4.03M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 17,702 shares for transaction amount of $26,907 was made by STANKOVICH THOMAS (Chief Financial Officer) on 2023‑06‑30.

List of Insider Buy and Sell Transactions, ReShape Lifesciences Inc.

2024-05-31SaleChief Financial Officer
48
0.0002%
$0.25$12-31.53%
2024-02-29SaleChief Financial Officer
43
0.0002%
$0.17$7+1.33%
2023-12-31SaleChief Financial Officer
42
0.0003%
$0.25$11-31.72%
2023-11-30SaleChief Financial Officer
39
0.0003%
$0.23$9-22.00%
2023-10-25SaleChief Financial Officer
131
0.0027%
$0.27$35-26.00%
2023-10-11SaleChief Financial Officer
39
0.0026%
$0.93$36-28.83%
2023-09-01SaleChief Financial Officer
118
0.0034%
$0.89$105-77.60%
2023-08-24SaleChief Financial Officer
39
0.0013%
$1.42$55-82.09%
2023-08-04SaleChief Financial Officer
108
0.0036%
$1.43$154-84.79%
2023-07-06SaleChief Financial Officer
106
0.0064%
$1.47$156-83.66%
2023-06-30PurchaseChief Financial Officer
17,702
1.0643%
$1.52$26,907-84.10%
2023-05-31SaleChief Financial Officer
98
0.0057%
$2.41$236-89.68%
2023-04-30SaleChief Financial Officer
96
<0.0001%
$2.36$227-64.13%
2023-03-31SaleChief Financial Officer
109
<0.0001%
$2.60$283-85.04%
2023-02-28SaleChief Financial Officer
103
<0.0001%
$4.25$438-76.97%
2023-02-02SaleChief Financial Officer
157
<0.0001%
$13.29$2,087-78.25%
2023-01-24SaleChief Financial Officer
158
<0.0001%
$7.49$1,183-81.24%
2022-12-01SaleChief Financial Officer
7,357
0.0335%
$0.15$1,112-69.71%
2022-11-28SaleChief Financial Officer
364,756
1.9555%
$0.17$61,826-68.05%
2022-11-04SaleChief Financial Officer
8,393
0.0385%
$0.27$2,287-82.14%

Insider Historical Profitability

34.16%
STANKOVICH THOMASChief Financial Officer
22777
4.4955%
$5.72633+4.59%
SABBY MANAGEMENT, LLC10 percent owner
1192507
235.3645%
$5.72100
DOMAIN PARTERS VII L P10 percent owner
813433
160.5468%
$5.7220
INTERWEST PARTNERS X LP10 percent owner
380224
75.0446%
$5.7220
Plovanic William J.President & CEO
106806
21.0802%
$5.7230

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.